Cardiology · Medical Literature
Ticagrelor versus clopidogrel in STEMI post-PCI: A mixed-design meta-analysis of efficacy and safety.
Abstract
ST-segment elevation myocardial infarction (STEMI) requires primary percutaneous coronary intervention (PCI) and dual antiplatelet therapy with aspirin and a purinergic receptor Y12 inhibitor to reduce thrombotic risks. Ticagrelor, a potent purinergic receptor Y12 inhibitor, offers faster and stronger platelet inhibition than clopidogrel, but evidence on its efficacy and safety in STEMI patients post-PCI is conflicting. This study aims to compare the efficacy and safety of ticagrelor versus clopidogrel in STEMI patients undergoing primary PCI. This systematic review and meta-analysis, adhering to Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines, searched PubMed, Embase, ScienceDirect, and ClinicalTrials.gov up to July 2025. Included were randomized controlled trials and observational studies comparing ticagrelor to clopidogrel in adult STEMI patients post-PCI, reporting cardiovascular outcomes. Data were pooled using odds ratios (ORs) with 95% confidence intervals (CIs) via random-effects models. Eight studies (5 randomized controlled trials, 3 observational; n = 31,729) showed ticagrelor significantly reduced all-cause mortality (OR = 0.64, 95% CI = 0.47-0.88; P = .006), cardiovascular mortality (OR = 0.68, 95% CI = 0.60-0.93; P = .01), major adverse cardiovascular events (OR = 0.71, 95% CI = 0.60-0.84; P = .01), myocardial infarction (OR = 0.71, 95% CI = 0.61-0.83; P < .00001), stent thrombosis (OR = 0.66, 95% CI = 0.55-0.79; P < .00001), and major bleeding (OR = 0.87, 95% CI = 0.78-0.97; P = .01), but increased target vessel revascularization (OR = 1.30, 95% CI = 1.05-1.61; P = .02). No significant difference was observed in stroke risk (OR = 1.16, 95% CI = 0.89-1.52; P = .28). Ticagrelor outperforms clopidogrel in STEMI post-PCI, reducing key adverse outcomes, though higher target vessel revascularization risk warrants caution.
Clinical relevance
In STEMI patients undergoing primary PCI, the optimal P2Y12 inhibitor strategy remains a subject of debate due to conflicting evidence across trials and real-world registries. This mixed-design meta-analysis (n = 31,729 across 8 studies) directly addresses this gap by pooling both RCT and observational data to provide a comprehensive efficacy and safety comparison of ticagrelor versus clopidogrel in this high-risk population. Clinicians managing acute STEMI should be aware of these findings given the immediate therapeutic decisions required at the time of intervention.
Key findings
1. Ticagrelor significantly reduced all-cause mortality compared to clopidogrel (OR = 0.64, 95% CI 0.47–0.88; P = .006), representing a 36% relative reduction in mortality risk. 2. Cardiovascular mortality was also significantly lower with ticagrelor (OR = 0.68, 95% CI 0.60–0.93; P = .01), a 32% relative risk reduction. 3. Major adverse cardiovascular events (MACE) were significantly reduced with ticagrelor (OR = 0.71, 95% CI 0.60–0.84; P = .01), reflecting a 29% relative reduction. 4. Ticagrelor significantly reduced recurrent myocardial infarction (OR = 0.71, 95% CI 0.61–0.83; P < .00001) and stent thrombosis (OR = 0.66, 95% CI 0.55–0.79; P < .00001), the latter representing a 34% relative reduction in a particularly feared post-PCI complication. 5. Contrary to prior concerns, ticagrelor was associated with significantly lower major bleeding rates versus clopidogrel (OR = 0.87, 95% CI 0.78–0.97; P = .01) in this pooled analysis. 6. Ticagrelor was associated with a significantly higher rate of target vessel revascularization (TVR) (OR = 1.30, 95% CI 1.05–1.61; P = .02), and no significant difference in stroke risk was observed between the two agents (OR = 1.16, 95% CI 0.89–1.52; P = .28).
Practice implications
For adult STEMI patients undergoing primary PCI, ticagrelor should be strongly favored over clopidogrel as the P2Y12 inhibitor component of dual antiplatelet therapy, given its superior reductions in all-cause mortality, cardiovascular mortality, MACE, MI, and stent thrombosis without an increase in major bleeding. The unexpected finding of increased target vessel revascularization with ticagrelor warrants careful post-discharge surveillance with scheduled functional or imaging follow-up, and this signal should be interpreted cautiously given the mixed RCT-observational study design and potential for residual confounding. Clopidogrel may remain an appropriate alternative in select patients where ticagrelor is contraindicated or not tolerated (e.g., significant bradyarrhythmia, concurrent strong CYP3A4 inhibitor use, or prior intracranial hemorrhage), but the overall benefit profile supports ticagrelor as the default agent in guideline-concordant STEMI management.